PIQUR Therapeutics AG

PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR’s lead compound, PQR309, is a novel, balanced pan-class 1 PI3K/mTOR inhibitor formulated for oral administration. Preclinical studies demonstrated that PQR309 is a highly selective kinase inhibitor, penetrating blood-brain barrier with potent in vitro as well as in vivo antitumor activity. A first-in-man clinical Phase 1 study was successfully completed and the maximum tolerated dose has been determined and has shown promising activity. PQR309 is currently engaged in multiple Phase 1 and Phase 2 studies as a single agent and as combination therapy.